PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30211553-6 2018 Likewise, pancaspase inhibitor z-vad-fmk, p38 MAPK inhibitor SB203580, and p53 depletion blocked PARP and caspase-3 in Kaempferol treated HCT116 colorectal cancer cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 31-40 caspase 3 Homo sapiens 106-115 30013780-8 2018 Furthermore, the caspase-3 activity of Huh-7 cells was increased by RID-B (0.5 and 5 microM), and the anti-proliferative effect of RID-B (1 microM) on Huh-7 cells was partially suppressed by the addition of the caspase inhibitor, Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 230-239 caspase 3 Homo sapiens 17-26 29223571-5 2018 NBCN-induced caspase 3- and 9-dependent DNA fragmentation, which was blocked by pretreatment with the broad-spectrum caspase inhibitor, z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 136-145 caspase 3 Homo sapiens 13-22 29754474-7 2018 Pre-treatment with Z-VAD-fmk, JNK inhibitor SP600125 and N-acetyl-l-cysteine (NAC), a ROS scavenger, partly improved the survival rates and restored OMT-induced cellular damage, and reduced caspase-3 cleavage. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 19-28 caspase 3 Homo sapiens 190-199 29660690-6 2018 However, general caspase inhibition by the pan-caspase inhibitor, z-VAD-fmk, significantly decreased the apoptosis induced by the tested hybrids, suggesting dependency of apoptosis on activation of the caspase-3 pathway. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 66-75 caspase 3 Homo sapiens 202-211 28676953-4 2018 However, pan-caspase inhibitor Z-VAD-FMK reversed the ability of gallotannin to activate caspase 3 at 48 h after treatment in two HCC cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 31-40 caspase 3 Homo sapiens 89-98 29084689-6 2017 However, caspase-3 inhibitor (z-VAD-FMK) couldn"t completely inhibit the curcumin induced apoptosis, indicating ROS mediated apoptosis may be caspase-independent. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 30-39 caspase 3 Homo sapiens 9-18 28487980-6 2017 Co-treatment with bortezomib and daunorubicin markedly enhanced the activation of caspase-3, -8 and -9, which was reversed by the pan-caspase inhibitor, Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 153-162 caspase 3 Homo sapiens 82-102 26873485-10 2016 Treatment of bladder cancer cells with Z-VAD-FMK + hepaCAM significantly downregulated procaspase 3/8/9 and PARP and induced cellular apoptosis, compared with that using Z-VAD-FMK alone. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 39-48 caspase 3 Homo sapiens 87-103 28317437-4 2017 These effects were cancelled by the addition of caspase inhibitor Z-VAD-FMK, suggesting that it was mediated by caspase-3 activation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 66-75 caspase 3 Homo sapiens 112-121 27456663-9 2017 However, in the zVAD pretreated cells, necroptotic cell death with a significant increase in expression of RIP1, RIP3, and MLKL genes was observed Conclusion: The novel hybrid benzoxazole-coumarins effectively induce Caspase-3 dependent apoptosis in HN-5 cancer cells, but also could circumvent the blockage of apoptotic cell death by induction of necroptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 16-20 caspase 3 Homo sapiens 217-226 27513956-10 2016 The SBL-induced caspase-3/7 activation was suppressed by the p38 MAPK inhibitor, SB203580, as well as pan-caspase inhibitor, zVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 125-133 caspase 3 Homo sapiens 16-25 25634589-10 2015 Z-VAD-FMK, a cell-permeable pan-caspase inhibitor, suppressed the activation of caspase-3 and PARP. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-9 caspase 3 Homo sapiens 80-89 26448608-3 2016 Chal-24 treatment significantly enhanced TRAIL-induced activation of caspase-8 and caspase-3, and the cytotoxicity induced by combination of these agents was effectively suppressed by the pan-caspase inhibitor z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 210-219 caspase 3 Homo sapiens 83-92 26440554-11 2015 Down regulation of pro caspase 3 was inhibited by Z-VAD-fmk (inhibitor of caspase). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 50-59 caspase 3 Homo sapiens 23-32 26503508-7 2015 The pan-caspase inhibitor Z-VAD-fmk suppressed the activation of caspase-3 and prevented cytotoxicity in FaDu cells treated with berberine. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 26-35 caspase 3 Homo sapiens 65-74 25772545-5 2015 DTC1 could inhibit proliferation, and highly induce apoptosis in HeLa cells by activating caspase-3, -6 and -9; moreover, activities of caspase-3, -6 and -9 were inhibited by pan-caspase inhibitor, Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 198-207 caspase 3 Homo sapiens 136-156 26890137-4 2016 Moreover, we found that the inhibition of caspase-3/7 activity by z-VAD-fmk treatment was able to block chaetocin-mediated cell death, whereas blocking autophagy by Bafilomycin A1 or the knockdown of autophagy protein 5 enhanced cell death mediated by chaetocin. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 66-75 caspase 3 Homo sapiens 42-51 25521557-8 2015 The release of caspase-3, caspase-8, and caspase-9 was stimulated by AG4 in CNE, and the decreased proliferation induced by AG4 was blocked by the inhibitor of pan caspase (Z-VAD-FMK). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 173-182 caspase 3 Homo sapiens 15-24 24727941-9 2014 Furthermore, the combined treatment markedly increased the cleaved PARP and cleaved caspase 3 in H460 cells, which were partly reversed by pretreatment with the caspase inhibitor zVAD.fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 179-183 caspase 3 Homo sapiens 84-93 25066322-6 2014 G226 induced dose-dependent apoptosis of MDA-MB-231 and MCF-7 cells, accompanied by markedly increased activities of caspase-8 and caspase-3/7, which were abolished by caspase inhibitors zVAD or zIETD. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 187-191 caspase 3 Homo sapiens 131-140 25973001-7 2015 In addition, z-VAD-fmk, a universal inhibitor of caspases, prevented caspase-3 activation and PARP cleavage and inhibited neogrifolin-induced cell growth inhibition. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 13-22 caspase 3 Homo sapiens 69-78 25342427-10 2014 Moreover, the highest activity of caspase-3 in DN-treated A549 cells was detected within the first 24 h, and pretreatment with the general caspase inhibitor z-VAD-fmk completely abolished such activity and also DN-induced apoptosis in a dose-dependent manner. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 157-166 caspase 3 Homo sapiens 34-43 24841638-7 2014 Further mechanistic analysis suggested that miR-451 overexpression accelerated cell death in a caspase-3-dependent manner, as pretreatment with its inhibitor z-VAD-fmk notably attenuated miR-451-induced cell apoptotic rates. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 158-167 caspase 3 Homo sapiens 95-104 24890449-6 2014 Pretreatment with a pan-caspase inhibitor, z-VAD-fmk, abrogated TQ-induced apoptosis by blocking the cleavage of caspase-3 and PARP. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 43-52 caspase 3 Homo sapiens 113-122 24768707-1 2014 The caspase inhibitor benzyloxycarbony (Cbz)-l-Val-Ala-Asp (OMe)-fluoromethylketone (z-VAD-FMK) has recently been shown to inhibit T cell proliferation without blocking caspase-8 and caspase-3 activation in primary T cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 85-94 caspase 3 Homo sapiens 183-192 24789703-6 2014 Furthermore, the changes in the levels of pro-caspase-3, -8 and -9 and cleaved caspase-3, -8 and -9 were abolished by the pan-caspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 144-153 caspase 3 Homo sapiens 42-99 24722468-4 2014 Cells containing mutant p150glued aggregates underwent apoptosis that was characterized by an increase in cleaved caspase-3- or Annexin V-positive cells and was attenuated by both zVAD-fmk (a pan-caspase inhibitor) application and caspase-3 siRNA knockdown. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 180-188 caspase 3 Homo sapiens 114-123 24722468-4 2014 Cells containing mutant p150glued aggregates underwent apoptosis that was characterized by an increase in cleaved caspase-3- or Annexin V-positive cells and was attenuated by both zVAD-fmk (a pan-caspase inhibitor) application and caspase-3 siRNA knockdown. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 180-188 caspase 3 Homo sapiens 231-240 24608674-10 2014 Co-exposure to the caspase-3 inhibitor zVAD-fmk (10 mumol/L) compromised the icaritin-induced caspase-3 expression and apoptosis in SaOS2 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 39-47 caspase 3 Homo sapiens 19-28 24608674-10 2014 Co-exposure to the caspase-3 inhibitor zVAD-fmk (10 mumol/L) compromised the icaritin-induced caspase-3 expression and apoptosis in SaOS2 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 39-47 caspase 3 Homo sapiens 94-103 23410748-5 2013 Although TNF-induced proteolytic activation of procaspase-3 was completely prevented by Z-VAD-fmk or Z-DEVD-fmk, the partial proteolysis of procaspase-3 was induced in the presence of Z-Asp-CH2-DCB. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 88-97 caspase 3 Homo sapiens 47-59 24025141-5 2013 Caspase-3/7 activity was suppressed by z-VAD-FMK and analyzed by homogeneous luminescence assay. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 39-48 caspase 3 Homo sapiens 0-9 25124618-5 2014 Additionally, MBS treatment led to activation of caspase-9, caspase-8 and caspase-3, and cleavage of PARP, which was abolished by pretreatment with the pan-caspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 174-183 caspase 3 Homo sapiens 74-83 24923653-10 2014 Cleaved caspase 9 and caspase 3 as well as apoptosis induced by ALA-SDT could be inhibited by Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 94-103 caspase 3 Homo sapiens 22-31 24213358-6 2014 To further investigate its mechanisms, the levels of apoptosis and the changes in caspase-3/9 expression in HEC-1B cells by pretreatment with z-VAD-fmk, a pan-caspase inhibitor, were detected by CCK-8 and western blotting. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 142-151 caspase 3 Homo sapiens 82-93 24039967-6 2013 Moreover, caspase-8 and caspase-3 activation and PARP-1 cleavage were strongly inhibited/blocked by the addition of the specific caspase inhibitors Z-VAD-FMK and Ac-DEVD-CHO. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 148-157 caspase 3 Homo sapiens 24-33 25337544-9 2013 Rg3 also induced the proteolytic cleavage of caspase-3 and poly (ADP-ribose) polymerase, which was attenuated by a caspase-3 inhibitor, z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 136-145 caspase 3 Homo sapiens 45-87 25337544-9 2013 Rg3 also induced the proteolytic cleavage of caspase-3 and poly (ADP-ribose) polymerase, which was attenuated by a caspase-3 inhibitor, z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 136-145 caspase 3 Homo sapiens 45-54 23123054-6 2013 Denbinobin evoked caspase-3 activation and degradation of poly (ADP-ribose) polymerase (PARP) and N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk), a broad-spectrum caspase inhibitor that prevented denbinobin-induced cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 150-158 caspase 3 Homo sapiens 18-27 23442976-7 2013 The caspase-3 mediated cleavage of Par-4 is blocked by addition of the pan-caspase inhibitor z-VAD-fmk, caspase-3 specific inhibitor Ac-DEVD-CHO, and by introduction of alanine substitution for D131 residue. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 93-102 caspase 3 Homo sapiens 4-13 23942225-3 2013 METHODS: In the present study, by using Z-VAD-fmk to inhibit caspase-3 in p53-deficient Hep3B cells, we explored the effect of Cr(VI) on apoptosis induction and the related mechanisms when the functions of p53 and caspase were simultaneously blocked. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 40-49 caspase 3 Homo sapiens 61-70 22853710-7 2012 Interestingly, Z-Val-Ala-Asp fluoromethyl ketone, a caspase 3 inhibitor, pre-treatment induces ProTalpha release from astrocytes in the ischemic brain, but this release is reversibly blocked by amlexanox. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 15-48 caspase 3 Homo sapiens 52-61 23011180-9 2012 Caspase inhibitor zVAD increased autophagosome formation, decreased the cleavage of caspase 3 and PARP but didn"t rescue the cells from LBH589-induced cell death in crystal violet staining suggesting both caspase-dependent as well as caspase-independent apoptosis pathways. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 18-22 caspase 3 Homo sapiens 84-93 22661476-9 2012 The expression levels of caspase-3 and caspase-9 were down-regulated after Z-VAD-FMK treatment. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 75-84 caspase 3 Homo sapiens 25-34 22878643-10 2012 CI-IB-MECA induced caspase-3 activation and the CI-IB-MECA-induced cell death was blocked by the caspase inhibitors DEVD-CHO and z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 129-138 caspase 3 Homo sapiens 19-28 22739153-11 2012 The little cleavage of PARP-1 and activation of caspase-3 happened in AA005-induced cell death, and caspase-3 inhibitor Z-VAD-fmk could not block the cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 120-129 caspase 3 Homo sapiens 100-109 21822542-8 2011 MYGJ induced anoikis in Bel-7402 cells accompanied by caspase-3, -8 and -9 activation, which was blocked by the pan-caspase inhibitor, Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 159-168 caspase 3 Homo sapiens 66-86 22471589-11 2012 Treatment of Z-VAD-fmk attenuated caspase-3 activity and significantly reversed the H(2)O(2) or TNF alpha-induced apoptosis in OLFM4 knockdown cells (all P < 0.01). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 13-22 caspase 3 Homo sapiens 34-43 22391177-5 2012 Compared with the group treated with As(2)O(3) (10 micromol/L) alone, zVAD-fmk (20 micromol/L) combined with As(2)O(3) (10 micromol/L) treatment group showed significant increase of expressions of Caspase-3 and BCL-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 70-78 caspase 3 Homo sapiens 197-206 22128871-8 2012 The dose-response curve of a caspase inhibitor Z-VAD-FMK was evaluated by caspase 3 assay, by which the IC(50) value was determined to be 0.73 muM and was in a good agreement with the literature reported value at 0.62 muM. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 47-56 caspase 3 Homo sapiens 74-83 22687398-7 2012 However, the changes of pro-caspase-3 and cleaved caspase-3 could be abolished by the pan-caspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 108-117 caspase 3 Homo sapiens 24-37 22991494-7 2012 15d-PGJ(2) induced chromatin-condensation and elevated caspase-3 activity, and the cell viability was restored by co-treatment with a pan-caspase inhibitor, Z-VAD-FMK, indicating the involvement of caspase-dependent apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 157-166 caspase 3 Homo sapiens 55-64 22223345-6 2012 PA activated caspase-3, -9, and poly(ADP-ribose) polymerase, and this effect was inhibited by z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 94-103 caspase 3 Homo sapiens 13-26 21082355-9 2011 ROS scavenger-N-acetyl cysteine, mitochondrial stabilizer-cyclosporin-A, and broad spectrum caspase inhibitor Z-VAD-FMK inhibited the OA induced caspase-3 activation, DNA damage and cell death but caspase-8 inhibitor had no effect. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 110-119 caspase 3 Homo sapiens 145-154 20717931-11 2011 It also induced mitochondrial depolarization, increased caspase-3/7 and -9 activity, and these increases were partially suppressed by pan-caspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 156-165 caspase 3 Homo sapiens 56-74 21308747-8 2011 Pre-treatment with caspase 3 inhibitor z-VAD-fmk and Ser/Thr phosphatase inhibitor abrogates the effect of SPH on facilitating apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 39-48 caspase 3 Homo sapiens 19-28 20799280-5 2011 zVAD-fmk, a broad-spectrum caspase inhibitor, inhibited As2O3-induced apoptosis and activation of caspase-3, but not that of JNK1/2 and ERK1/2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-8 caspase 3 Homo sapiens 98-107 19920200-6 2009 This XIAP inhibitor-induced and TRAIL-induced apoptosis involves caspase-3 activation and is blocked by the caspase inhibitor zVAD.fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 126-130 caspase 3 Homo sapiens 65-74 21881314-8 2011 The results showed that delta-elemene could induce caspase-3 activation as detected by the decrease in delta-elemene-induced caspase-3 activities after treatment with z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 167-176 caspase 3 Homo sapiens 51-60 21881314-8 2011 The results showed that delta-elemene could induce caspase-3 activation as detected by the decrease in delta-elemene-induced caspase-3 activities after treatment with z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 167-176 caspase 3 Homo sapiens 125-134 20619960-3 2010 The wide ranging caspase inhibitor z-VAD fmk prevented the cleavage of caspase-3 and 4E-BP1, but failed to attenuate PARP-1 cleavage or cell death triggered by CF(3)-STLC. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 35-44 caspase 3 Homo sapiens 71-91 19647729-7 2009 Apigenin-induced apoptotic cell death was mediated through activation of the effectors caspase-3 and caspase-7, and was blocked by pretreatment with Z-VAD-FMK (a pan-caspase inhibitor). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 149-158 caspase 3 Homo sapiens 87-96 21747710-9 2011 However, the changes of pro-caspase-3 and activated caspase-3 could be abolished by a pan-caspase inhibitor ZVAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 108-116 caspase 3 Homo sapiens 24-37 21747710-9 2011 However, the changes of pro-caspase-3 and activated caspase-3 could be abolished by a pan-caspase inhibitor ZVAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 108-116 caspase 3 Homo sapiens 28-37 20580860-4 2010 Kinetic studies of caspase-3 and caspase-8 inhibition were carried out with these urazole ring-containing irreversible peptidomimetics and a known irreversible caspase inhibitor, Z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 179-188 caspase 3 Homo sapiens 19-28 20580860-6 2010 Z-VAD-fmk and the peptidomimetic inhibitors inhibit caspase-3 and caspase-8 via a three-step kinetic mechanism. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-9 caspase 3 Homo sapiens 52-61 20580860-7 2010 Inhibition of both caspase-3 and caspase-8 by Z-VAD-fmk and of caspase-3 by the peptidomimetic inhibitors proceeds via two rapid equilibrium steps followed by a relatively fast inactivation step. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 46-55 caspase 3 Homo sapiens 19-28 20512627-8 2010 Pretreatment with z-VAD-fmk markedly prevented caspase-3 activation and moderately suppressed apoptosis, suggesting that Dox + DMPS-induced apoptosis is somewhat (not completely) dependent on caspase. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 18-27 caspase 3 Homo sapiens 47-56 20232365-5 2010 Apoptosis was associated with caspase-3 activity and poly(ADP-ribose) polymerase cleavage and was prevented by the nonspecific caspase inhibitor z-VAD-fmk, indicating that caspases are essential components in this pathway. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 145-154 caspase 3 Homo sapiens 30-39 20227390-6 2010 In addition, pretreatment with a pan-caspase inhibitor, zVAD-fmk, attenuated the levels of caspase-3 activation and PARP cleavage in radiation-exposed cancer cells in combination with rosiglitazone pretreatment. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 56-64 caspase 3 Homo sapiens 91-100 20402812-13 2010 However, pretreatment of INT407 cells with caspase inhibitor (Z-VAD-FMK) inhibited the activation of caspase 3/7 and 9. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 62-71 caspase 3 Homo sapiens 101-118 19360361-4 2009 A pan-caspase inhibitor, z-VAD-fmk, suppressed this increase in apoptosis and also suppressed the cleavage of caspase-8, caspase-3, and PARP, suggesting a caspase-dependent mechanism. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 25-34 caspase 3 Homo sapiens 121-130 19652385-5 2009 Furthermore, this study showed that amentoflavone, at a concentration greater than 75 microM, increased the cleavage-activity of caspase-3 and poly (ADP-ribose) polymerase (PARP), and administration of pan-caspase inhibitor Z-VAD-FMK completely rescued the SK-BR-3 cells from PARP cleavages. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 224-233 caspase 3 Homo sapiens 129-171 19248798-7 2009 Normal caspase-3 activity levels were observed when Z-VAD-FMK, a caspase inhibitor, was added simultaneously with the ENs. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 52-61 caspase 3 Homo sapiens 7-16 19118093-8 2009 In A549 cells, T/HS lymph activated caspase-3-mediated apoptosis, which was partially abrogated by N-benzyloxycarbonyl-Val-Ala-Asp (zVAD). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 132-136 caspase 3 Homo sapiens 36-45 19523979-6 2009 Pretreatment of OLPs with the pan-caspase inhibitor, zVAD-fmk, prevented caspase-3 activation but only slightly reduced cell death 11h after cadmium exposure and failed to prevent cadmium-induced bax insertion into the mitochondrial membrane. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 53-61 caspase 3 Homo sapiens 73-82 19235152-5 2009 Pretreatment of a pan-caspase inhibitor (benzyloxycarbonyl)-Val-Ala-Asp-(fluoromethyl) ketone (z-VAD-fmk) significantly increases the viability of 1-treated HeLa cells implied that the participation of caspase; Western-blot analysis showed the activation of initiator caspase-8 and caspase-9, and executor caspase-3. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 95-104 caspase 3 Homo sapiens 306-315 18373093-11 2009 Co-administration of Z-VAD-FMK, a pan-caspase inhibitor, blocked NSC-induced caspase 3/7 activity and cell apoptosis without affecting NSC-induced cell cycle arrest. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 21-30 caspase 3 Homo sapiens 77-86 19255516-9 2009 The decrease of pHi and of DeltapHi following NS1 expression could be significantly blunted by inhibition of caspase 3 with zVAD. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 124-128 caspase 3 Homo sapiens 109-118 18459128-6 2009 Treatment of the cells with pan-caspase inhibitor (z-VAD-fmk) or caspase-3 inhibitor (z-DEVD-fmk) inhibited berberine-induced apoptosis, thus suggesting the role of caspase-3. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 51-60 caspase 3 Homo sapiens 165-174 19152031-3 2009 QM31 was as efficient as Z-VAD-fmk in suppressing caspase-3 activation, and conferred a similar cytoprotective effect. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 25-34 caspase 3 Homo sapiens 50-59 18068200-9 2008 Caspase-3/7 activation was inhibited partially by low density lipoprotein (LDL), high density lipoprotein (HDL), z-VAD-fmk (pan-caspase inhibitor), and low doses (0.01 and 0.001 microM) of the cholesterol lowering drug, simvastatin. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 113-122 caspase 3 Homo sapiens 0-9 18818525-7 2008 Although pretreatment with zVAD completely inhibited caspase-3 activation by 3MA, it did not prevent cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 27-31 caspase 3 Homo sapiens 53-62 18981398-7 2008 Interestingly, inhibition of caspase-3 by Z-VAD-FMK did not suppress apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 42-51 caspase 3 Homo sapiens 29-38 18662322-3 2008 ENZA-induced apoptosis involved cleavage of caspases 3, 8, and 9 and led to mitochondrial cytochrome c release and was strongly suppressed by the broad spectrum caspase inhibitor zVAD-fmk but only slightly by the expression of the viral caspase 1/8 inhibitor cytokine response modifier-A. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 179-187 caspase 3 Homo sapiens 44-64 18582399-6 2008 Caspases 3, 8 and 9 were activated in Jurkat cells and the caspase specific inhibitors, such as broad caspases inhibitor Z-VAD-FMK, caspase 8 specific inhibitor Z-IETD-FMK and caspase 9 specific inhibitor Z-LEHD-FMK could recover the viability loss caused by A6. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 121-130 caspase 3 Homo sapiens 0-19 17854772-4 2007 Treatment of erythrocytes with caspase inhibitors Z-VAD-fmk or Z-DQMD-fmk (caspase 3 selective) before the oxidation resulted in lowered binding of the oxidized erythrocytes to macrophages, suggesting that actions of caspases, particularly those of caspase 3, are prerequisite for the membrane changes leading to band 3 aggregation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 50-59 caspase 3 Homo sapiens 249-258 18281497-6 2008 Cotreatment with the caspase-3 inhibitor Z-VAD-FMK abrogated the effect of FTY720 on facilitating PKC delta proteolysis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 41-50 caspase 3 Homo sapiens 21-30 18175943-3 2008 Activity of caspase-3 was extensively increased in U266 cells treated with Phx-3 time-dependently within 24 h, but this Phx-3-stimulated activity of the enzyme in the cells was completely cancelled by the addition of N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk), a pan-caspase inhibitor. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 269-278 caspase 3 Homo sapiens 12-21 17373651-8 2007 Inhibition by zVAD-fmk caused slight MW increase in p17 and emergence of p19, which indicates that the inhibitor caused partial processing of caspase-3. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 14-22 caspase 3 Homo sapiens 142-151 17512926-6 2007 Although the activity of caspase-3, which has direct effect on apoptosis, was also enhanced by the presence of andrographolide, cell death of HepG2 could neither be prevented by a specific inhibitor of capsase-3 nor the pan-caspase inhibitor-zVAD (Val-Ala-Asp), indicating that it was a caspase-independent cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 242-246 caspase 3 Homo sapiens 25-34 17333316-6 2007 In addition, z-VAD-fmk, a universal inhibitor of caspases, prevented caspase-3 activation and PARP cleavage and inhibted grifolin-induced cell growth inhibition. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 13-22 caspase 3 Homo sapiens 69-78 17549379-7 2007 The broad-spectrum caspase inhibitor zVAD-fmk abrogated GP7-induced caspase-3, -8, and -9 activations but could not inhibit GP7-induced apoptotic DNA fragmentation in NB4 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 37-45 caspase 3 Homo sapiens 68-89 17904792-6 2007 Procaspase-3 was also found to be processed into the active and smaller 17 and 19 kDa subunits, and administration of pan-caspase inhibitor Z-VAD-FMK completely rescued the cells from PARP cleavage. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 140-149 caspase 3 Homo sapiens 0-12 17970084-4 2007 In CaSki cells pretreated with the pan-caspase inhibitor zVAD-fmk, the berberine-induced caspase-3 activity and apoptosis were significantly blocked as confirmed by flow cytometric analysis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 57-65 caspase 3 Homo sapiens 89-98 17437185-8 2007 Cleavage of procaspase-8 was susceptible to inhibition by z-VAD-fmk and to the caspase-3 inhibitor Ac-DMQD-CHO, indicating a contribution to the activation of caspase-3 in an amplifying manner. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 58-67 caspase 3 Homo sapiens 159-168 17575108-4 2007 The cells expressing the modified FADD underwent apoptosis through the typical apoptosis cascade via activation of caspase-3, and apoptosis was inhibited by a caspase inhibitor (i.e., z-VAD-fmk). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 184-193 caspase 3 Homo sapiens 115-124 17437483-5 2007 Pretreatment with the pan-caspase inhibitor (z-VAD-fmk) blocked the GSP-induced apoptosis in A431 cells suggesting that GSP-induced apoptosis is associated primarily with the caspase-3-dependent pathway. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 45-54 caspase 3 Homo sapiens 175-184 17122150-7 2006 7kCh-induced caspase-3 activation was blocked by z-VAD-fmk (P < 0.001). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 49-58 caspase 3 Homo sapiens 13-22 17352223-4 2007 The results showed that baicalin induced cytotoxicity in a dose- and time-dependent manner through the activation of caspase-3, as shown by treatment of HL-60 cells with an inhibitor of caspase-3 (z-VAD-fmk). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 197-206 caspase 3 Homo sapiens 117-126 17352223-4 2007 The results showed that baicalin induced cytotoxicity in a dose- and time-dependent manner through the activation of caspase-3, as shown by treatment of HL-60 cells with an inhibitor of caspase-3 (z-VAD-fmk). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 197-206 caspase 3 Homo sapiens 186-195 17136492-4 2007 Hypoxia or TRAIL-induced activation of cathepsins (B, D and L), caspases (-3 and -9), Bid cleavage, release of Bax and cytochrome c, and DNA fragmentation were blocked independently by zVAD-fmk, CA074Me or pepstatin A, consistent with the involvement of lysosomal cathepsin B and D in cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 185-193 caspase 3 Homo sapiens 64-83 17453707-7 2007 The pan-caspase inhibitor z-VAD-fmk can block the activation of caspase 3, 9 and PARP cleavage. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 26-35 caspase 3 Homo sapiens 64-73 16990604-6 2007 FcalphaRI-mediated apoptosis signals were blocked by treatment with the pan-caspase inhibitor zVAD-fmk, involved proteolysis of procaspase-3, and correlated negatively with SHP-1 concentration. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 94-102 caspase 3 Homo sapiens 128-140 17007887-9 2006 The experiments using inhibitors of caspases (Z-VAD-FMK, Z-DEVD-FMK and Z-IETD-FMK) confirmed that caspase-3 was involved in the apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 46-55 caspase 3 Homo sapiens 99-108 17203181-5 2007 The activity of effector caspase-3 significantly increased in MKN45 treated with Phx-3 for 24 h, but did not altered in the cells treated with Phx-1 for 24 h. When z-VAD-fmk, a pan-caspase inhibitor, was co-treated for 24 h, Phx-3-stimulated caspase-3 activity in MKN45 was reversed to the levels of normal activity, while the antiproliferative and apoptotic effects of Phx-3 against the cells were maintained. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 164-173 caspase 3 Homo sapiens 25-34 17203181-5 2007 The activity of effector caspase-3 significantly increased in MKN45 treated with Phx-3 for 24 h, but did not altered in the cells treated with Phx-1 for 24 h. When z-VAD-fmk, a pan-caspase inhibitor, was co-treated for 24 h, Phx-3-stimulated caspase-3 activity in MKN45 was reversed to the levels of normal activity, while the antiproliferative and apoptotic effects of Phx-3 against the cells were maintained. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 164-173 caspase 3 Homo sapiens 242-251 17201156-9 2006 The inhibition of caspase-3 activation by z-VAD-fmk (broad-spectrum caspase inhibitor) completely blocked curcumin-induced apoptosis in HL-60 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 42-51 caspase 3 Homo sapiens 18-27 16893617-6 2006 Pretreatment with a general caspase inhibitor, Z-VAD.fmk, prevented cleavage of caspase-3 but demonstrated a slight improvement of cytotoxicity induced by TRO. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 47-56 caspase 3 Homo sapiens 80-89 16621886-6 2006 Pretreatment of A431 cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked the berberine-induced apoptosis in A431 cells confirmed that berberine-induced apoptosis is mediated through activation of caspase 3-dependent pathway. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 59-68 caspase 3 Homo sapiens 215-224 16574901-6 2006 Activation of caspase-3 was detected after MCPIP transfection and Z-VAD-fmk partially inhibited cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 66-75 caspase 3 Homo sapiens 14-23 16645590-4 2006 Enzastaurin-induced cell death involved caspase-3-activated cleavage of poly(ADP-ribose) polymerase that was inhibited by the pan-caspase inhibitor ZVAD-fmk, whereas the increase in sub-G1 population was only partially inhibited by ZVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 148-156 caspase 3 Homo sapiens 40-49 16645590-4 2006 Enzastaurin-induced cell death involved caspase-3-activated cleavage of poly(ADP-ribose) polymerase that was inhibited by the pan-caspase inhibitor ZVAD-fmk, whereas the increase in sub-G1 population was only partially inhibited by ZVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 232-240 caspase 3 Homo sapiens 40-49 16140185-6 2005 We also measured the inhibition of paclitaxel-induced apoptosis and the caspase-3 activity by the broad-spectrum caspase inhibitor z-VAD-fmk on U-2 OS cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 131-140 caspase 3 Homo sapiens 72-81 16502262-7 2006 In addition, zVAD-fmk, a universal inhibitor of caspases, prevents caspase-3 activation and abrogates cell death induced by curcumin treatment. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 13-21 caspase 3 Homo sapiens 67-76 16475703-7 2006 Inhibition of caspase-3 activation (z-VAD-fmk: cell-permeable broad-spectrum caspase inhibitor) completely blocked berberine-induced apoptosis in both HL-60 and WEHI-3 cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 36-45 caspase 3 Homo sapiens 14-23 16211219-7 2005 Z-VAD-fmk (a pan-caspase inhibitor) perfectly inhibited the up-regulation of caspase-3 but failed to reverse the cell viability. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-9 caspase 3 Homo sapiens 77-86 15609279-2 2005 Fucoidan-induced apoptosis was accompanied by the activation of caspase-3 and was partially prevented by pretreatment with a pan-caspase inhibitor, z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 148-157 caspase 3 Homo sapiens 64-73 15710362-9 2005 Activation of caspase-3, cleavage of PARP and DNA fragmentation was blocked by pre-treatment with caspase-3 specific inhibitor Ac-DEVD-CHO (100 microM) and broad-spectrum caspase inhibitor Z-VAD-FMK (40 microM). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 189-198 caspase 3 Homo sapiens 14-23 15876477-6 2005 General caspase inhibitor, Z-VAD-FMK, inhibited completely the caspase-3 activity, reduced DNA cleavage but did not prevent the spontaneous or valinomycin-induced apoptosis of NK cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 27-36 caspase 3 Homo sapiens 63-72 15698862-9 2005 The pretreatment of cells with Caspase-3 inhibitor ZVAD-fmk significantly inhibited meconium-induced lung cell death by apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 51-59 caspase 3 Homo sapiens 31-40 16292754-3 2005 The crucial role of caspase-3 was supported by the use of z-VAD-fmk and z-DEVD-fmk, which abolished apoptosis and the associated events. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 58-67 caspase 3 Homo sapiens 20-29 15451183-6 2004 The DNA laddering coincided with the detection of caspase 3 and PARP-1 cleavage and was dependent upon activation of the caspase pathway, since treatment with Z-VAD-FMK, a pan-caspase inhibitor, inhibited both events. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 159-168 caspase 3 Homo sapiens 50-59 15681813-8 2004 The proteolytic activation of PKCdelta was suppressed by treatment with 100 microM Z-VAD-FMK and 100 microM Z-DEVD-FMK, suggesting that caspase-3 mediates the proteolytic activation of PKCdelta. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 83-92 caspase 3 Homo sapiens 136-145 15477863-10 2004 Western blot analysis showed a specific cleavage of procaspase-3 in apoptotic cells, which was inhibited by Z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 108-117 caspase 3 Homo sapiens 52-64 15657348-9 2005 Apigenin increased caspase-3 activity and PARP cleavage, and Z-VAD-FMK, a broad-spectrum caspase-3 inhibitor, rescued NUB-7 cells from apigenin-mediated apoptosis indicating that apigenin induced apoptosis in acaspase-dependent manner. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 61-70 caspase 3 Homo sapiens 89-98 15306200-6 2004 Carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK), a caspase inhibitor with a broad spectrum, inhibited caspase-3 activities stimulated by PKC412 and staurosporine; however, only PKC412-induced apoptosis, but not staurosporine-induced apoptosis, was prevented by Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 46-55 caspase 3 Homo sapiens 111-120 15306200-6 2004 Carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK), a caspase inhibitor with a broad spectrum, inhibited caspase-3 activities stimulated by PKC412 and staurosporine; however, only PKC412-induced apoptosis, but not staurosporine-induced apoptosis, was prevented by Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 270-279 caspase 3 Homo sapiens 111-120 15254772-4 2004 SEB induced the activation of caspase-3 and -8, and pre-treatment with z-VAD-fmk, a broad-spectrum inhibitor of caspases, prevented the induction of apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 71-80 caspase 3 Homo sapiens 30-46 15193998-6 2004 A broad spectrum caspase inhibitor, z-VAD-fmk, blocked caspase-3 activation and elevated the survival in LMB-treated U937 cells, suggesting that caspase-3 activation is critical for LMB-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 36-45 caspase 3 Homo sapiens 55-64 15193998-6 2004 A broad spectrum caspase inhibitor, z-VAD-fmk, blocked caspase-3 activation and elevated the survival in LMB-treated U937 cells, suggesting that caspase-3 activation is critical for LMB-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 36-45 caspase 3 Homo sapiens 145-154 15100281-6 2004 Although the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) decreased DNA fragmentation, cytochrome c release and caspase-9 and caspase-3 activation were not implicated, suggesting that this apoptosis did not primarily involve the intrinsic mitochondrial pathway. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 87-95 caspase 3 Homo sapiens 165-174 15148608-8 2004 Moreover, caspase-3 activity was completely blocked at zVAD-fmk concentrations of 1 microM in HeLa cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 55-63 caspase 3 Homo sapiens 10-19 15122333-4 2004 Inhibition of caspase-3 activity in TGCT cells with the broad-spectrum caspase inhibitor zVAD-fmk had no effect on p21 levels and also not upon cisplatin treatment. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 89-97 caspase 3 Homo sapiens 14-23 15214043-6 2004 In both cases, partial processing of caspase-3 was observed in the presence of zVAD. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 79-83 caspase 3 Homo sapiens 37-46 15214043-7 2004 By expression in 293 cells we addressed the potential of candidate initiator caspases to function in the presence of zVAD, and found that caspase-9 efficiently processed caspase-3, while caspase-2 or -8 were inactive. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 117-121 caspase 3 Homo sapiens 170-179 15009026-5 2004 Cells treated with Mcf show apoptotic nuclear morphology, active caspase-3, DNA laddering after 6 h, and the presence of cleaved PARP after 16 h. These effects are prevented by the apoptosis inhibitor zVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 201-209 caspase 3 Homo sapiens 65-74 12115564-10 2002 Pretreatment with the broad-spectrum caspase inhibitor z-VAD-fmk markedly inhibited NCTD-induced caspase-3 activity and cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 55-64 caspase 3 Homo sapiens 97-106 15115612-6 2004 The activity of caspase-3, which is one of the major executioner caspases, was found to be inhibited by both Z-DEVD-MFK and Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 124-133 caspase 3 Homo sapiens 16-25 14514658-4 2004 SFN-induced apoptosis, and cleavage of procaspase-3 and PARP were blocked upon pre-treatment of cells with pan caspase inhibitor z-VADfmk, and specific inhibitors of caspase-9 (z-LEHDfmk) and caspase-8 (z-IETDfmk) suggesting involvement of both caspase-9 and caspase-8 pathways in SFN-induced cell death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 129-137 caspase 3 Homo sapiens 39-51 14754601-13 2004 Fas-induced caspase 3 cleavage, and cell death was inhibited by zVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 64-72 caspase 3 Homo sapiens 12-21 12670894-5 2003 The caspase-8-specific inhibitor z-IETD-fmk, as well as pan-caspase inhibitor z-VAD-fmk, but not the calpain inhibitor E-64d, prevents Bid cleavage, Bax conformational change, and subsequent caspase-3 processing and apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 78-87 caspase 3 Homo sapiens 191-200 12700632-4 2003 Exogenous ROS and caspase-3 induced deltapsi(m) drop and cytochrome c release from mitochondria, which could be prevented by molecular (dominant-negative caspase-9) and pharmacologic (zVAD-fmk) caspase inhibitors and overexpression of Bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 184-192 caspase 3 Homo sapiens 18-27 12579342-5 2003 A pan-caspase inhibitor, Z-VAD-fmk, completely blocked H2O2-induced procaspase-3 proteolysis and PARP cleavage without changing Bax cleavage, but partially attenuated H2O2-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 25-34 caspase 3 Homo sapiens 68-80 12576187-8 2003 Application of the pancaspase inhibitor z-VAD-fmk almost completely abolished the formation of active caspase 3 protein and apoptotic nuclei induced by colchicine, but the formation of necrotic nuclei increased correspondingly and the PI uptake was unaffected. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 40-49 caspase 3 Homo sapiens 102-111 12431242-4 2002 Caspase-3 activation was shown to be a prerequisite for ATRA-induced apoptosis, which was inhibited by the pan-caspase inhibitor Z-VAD-FMK and the caspase-9 inhibitor Z-LEHD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 129-138 caspase 3 Homo sapiens 0-9 15009733-8 2004 It was thus of great interest to learn that addition of the caspase inhibitor Z-VADfmk decreased and interferon-gamma stimulation, which is known to upregulate caspase levels including caspase-3, increased the sensitivity of T cells toward UVA-1 radiation-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 78-86 caspase 3 Homo sapiens 185-194 11864973-6 2002 Cells treated with calpain-dependent inhibitor ALLN and apoptosis inhibitor zVAD-FMK suppressed degradation of IkappaBalpha and activation of caspase 3, respectively. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 76-84 caspase 3 Homo sapiens 142-151 12065694-8 2002 Both DEVD-fmk and ZVAD-fmk completely inhibited caspase 3 activity but, like PFT, partially inhibited cisplatin-induced chromatin condensation, annexin V labeling, and DNA hypoploidy after 24 h. These data demonstrate that at least 50% of cisplatin-induced apoptosis in RPTC is mediated by p53 and that p53 activates caspase 3 independently of either caspase 9 or 8 or mitochondrial dysfunction. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 18-26 caspase 3 Homo sapiens 48-57 11836632-11 2002 Cleavage of PARP was observed at 3-4 h following PDT and caspase-3 specific inhibitor DEVD-CHO and broad-spectrum caspases inhibitor z-VAD-fmk blocked caspase-3 activation and PARP cleavage suggesting that caspase-3 plays an important role in HA and HB-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 133-142 caspase 3 Homo sapiens 151-160 11836632-11 2002 Cleavage of PARP was observed at 3-4 h following PDT and caspase-3 specific inhibitor DEVD-CHO and broad-spectrum caspases inhibitor z-VAD-fmk blocked caspase-3 activation and PARP cleavage suggesting that caspase-3 plays an important role in HA and HB-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 133-142 caspase 3 Homo sapiens 151-160 11880503-4 2002 Pretreatment with caspase inhibitors (Z-DEVD-FMK or Z-VAD-FMK) blocked MMT-induced proteolytic cleavage of PKCdelta, indicating that cleavage is mediated by caspase-3. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 52-61 caspase 3 Homo sapiens 157-166 11640881-8 2001 The caspase-3 inhibitor ZVAD-fmk blocks 465*-dependent cell death when added acutely after electroporation, but fails to do so later. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 24-32 caspase 3 Homo sapiens 4-13 11781253-6 2002 The general caspase inhibitor z-Val-Ala-DL-Asp-fluoromethylketone (zVAD-fmk) prevented caspase-3 activation and apoptosis in PMNs, but not Bax redistribution. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 67-75 caspase 3 Homo sapiens 87-96 11781253-8 2002 zVAD-fmk inhibited both caspase-3 activation and phosphatidylserine exposure in cultured cytoplasts. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-8 caspase 3 Homo sapiens 24-33 11850837-7 2002 Cell death was greatly reduced by the caspase-3 inhibitor ZVAD.FMK, but not by the caspase-1 inhibitor Ac-YVAD.CHO. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 58-66 caspase 3 Homo sapiens 38-47 11795493-5 2001 zVAD-Fmk, a universal inhibitor of caspases, kept the caspase-3 from being activated but not caspase-9. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-8 caspase 3 Homo sapiens 54-63 11532973-3 2001 This form of apoptosis, inhibited by Z-VAD-fmk, was associated with a loss of mitochondrial potential, a cytosolic release of cytochrome c, activation of caspase-3, degradation of poly(ADP-ribose)polymerase, and internucleosomal DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 37-46 caspase 3 Homo sapiens 154-163 11675421-9 2001 Inhibition of caspase-3 by the use of the caspase-3 inhibitor acetyl-Asp-Glu-Val-Asp-fmk or the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone (zVAD-fmk) prevented features of apoptosis, such as morphologic changes, internucleosomal DNA degradation, and the appearance of hypodiploid cells and increased the number of viable, trypan blue-excluding neutrophils. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 182-190 caspase 3 Homo sapiens 14-23 11597611-10 2001 Finally, inhibition of caspase-3 activity by z-VAD-fmk only partially protected neurons from KA toxicity, implying that multiple mechanisms may be involved in KA excitotoxicity. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 45-54 caspase 3 Homo sapiens 23-32 11527401-4 2001 U0126/ara-C-mediated apoptosis and pro-caspase 3 activation, but not cytochrome c or Smac/DIABLO release, were blocked by the pan-caspase inhibitor ZVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 148-156 caspase 3 Homo sapiens 35-48 11507084-6 2001 Caspase-specific inhibitor, z-Val-Ala-Asp-fluoromethyl ketone prevented Bay 11-7085-induced activation of caspase 3 but was not able to block Bay 11-7085-induced phosphorylation of p38 MAP kinase. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 28-61 caspase 3 Homo sapiens 106-115 11389070-12 2001 Moreover, a caspase inhibitor, z-Val-Ala-Asp-fluoromethyl ketone, blocked ibandronate-induced DNA fragmentation in MDA-231 cells, suggesting an involvement of caspase-3 in ibandronate-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 31-64 caspase 3 Homo sapiens 159-168 11483620-5 2001 Activation of caspase-3-like enzyme occurred after addition of lysosphingolipids followed by incubation at 37 degrees C for 24 h. The addition of an inhibitor of caspases, ZVAD-fmk, to the Neuro2a cell culture completely inhibited the elevation of caspase-3 activity but not the DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 172-180 caspase 3 Homo sapiens 14-23 11490367-10 2001 Caspase 3 and 6 were upregulated by SNAP and significantly inhibited by ZVAD. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 72-76 caspase 3 Homo sapiens 0-9 11408917-11 2001 Furthermore, both active caspase-3 and apoptosis triggered by either ADR or 5-FU were inhibited significantly by the general caspase inhibitor Z-VAD-FMK, or a specific caspase-3 inhibitor DMQD-CHO. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 143-152 caspase 3 Homo sapiens 25-34 10934034-8 2000 In the presence of z-DEVD-FMK or Ac-YVAD-CMK, caspase-3 was processed to both the p17 and p20 fragments in staurosporine-treated cells, but only to p20 fragment in the presence of z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 180-189 caspase 3 Homo sapiens 46-55 11344312-7 2001 Activation of caspase-3 and total cleavage of poly(ADP-ribose) polymerase (PARP) occurred between 2 and 6 h posttreatment with avicins by zVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 138-146 caspase 3 Homo sapiens 14-23 11344045-6 2001 Bisphosphonate-induced osteoclast apoptosis was dependent on caspase activation, because apoptosis resulting from alendronate, clodronate, or zoledronic acid treatment was suppressed by zVAD-fmk, a broad-range caspase inhibitor, or by SB-281277, a specific isatin sulfonamide inhibitor of caspase-3/-7. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 186-194 caspase 3 Homo sapiens 289-301 11134047-4 2001 These apoptotic markers were suppressed by the addition of S1P, the NO donor S-nitroso-N-acetylpenicillamine (100 micrometer), or caspase-3 inhibitor z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 150-159 caspase 3 Homo sapiens 130-139 11160608-6 2001 Both the caspases inhibitors, ZVAD-fmk and DEVD-cho, inhibited at similar extent apoptosis induced by either DXR or MEN 10755, suggesting an involvement of caspase-3 in this response. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 30-38 caspase 3 Homo sapiens 156-165 11146441-12 2001 Both the tripeptide caspase inhibitor zVAD-fmk and the specific caspase-3 inhibitor DEVD-fmk partially suppressed As(2)O(3)-induced caspase-3 activation and apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 38-46 caspase 3 Homo sapiens 132-141 10970901-5 2000 Caspase inhibitors suppressed the DNA fragmentation in the order of Z-VAD-FMK > caspase-8 inhibitor > caspase-3 inhibitor. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 68-77 caspase 3 Homo sapiens 108-117 11152579-6 2000 IFN-alpha-induced apoptosis occurred 48 h after stimulation, with a further increase in proportion up to 72 h. Pretreatment with pancaspase inhibitor Z-VAD-fmk substantially inhibited the IFN-alpha-mediated Bax-alpha cleavage and apoptosis, but not the decline in Delta psi(m), suggesting the possibility that caspase-3 activation is implicated in the Bax-alpha cleavage, probably leading to amplification of the apoptotic processes. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 150-159 caspase 3 Homo sapiens 310-319 11002424-4 2000 The caspase inhibitors Z-VAD-FMK and Z-DEVD-FMK blocked apoptosis induced by CD437 in DU145 and LNCaP cells, in which increased caspase-3 activity and PARP cleavage were observed, but not in PC-3 cells, in which CD437 did not induce caspase-3 activation and PARP cleavage. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 23-32 caspase 3 Homo sapiens 128-137 11002424-4 2000 The caspase inhibitors Z-VAD-FMK and Z-DEVD-FMK blocked apoptosis induced by CD437 in DU145 and LNCaP cells, in which increased caspase-3 activity and PARP cleavage were observed, but not in PC-3 cells, in which CD437 did not induce caspase-3 activation and PARP cleavage. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 23-32 caspase 3 Homo sapiens 233-242 11313933-3 2001 This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 59-68 caspase 3 Homo sapiens 138-147 11277264-4 2001 In osteoblasts undergoing apoptosis, proteolytic cleavage of N-cadherin and beta- and gamma- catenins but not alpha-catenin was associated with the activation of caspase-3 and prevented by the caspase inhibitor Z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 211-220 caspase 3 Homo sapiens 162-171 11313717-7 2001 Both Zinc-mediated apoptosis and caspase-3 activation were prevented by the cell-permeable, broad-spectrum inhibitor of caspases (zVAD-fmk) or overexpression of bcl-2. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 130-138 caspase 3 Homo sapiens 33-42 10989191-9 2000 Activation of caspase-3/CPP32 and apoptosis upon growth factor withdrawal were inhibited/reduced by the caspase inhibitors, z-VAD-fmk and DEVD-CHO. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 124-133 caspase 3 Homo sapiens 14-23 10989191-9 2000 Activation of caspase-3/CPP32 and apoptosis upon growth factor withdrawal were inhibited/reduced by the caspase inhibitors, z-VAD-fmk and DEVD-CHO. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 124-133 caspase 3 Homo sapiens 24-29 10825467-8 2000 The general caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone and the specific caspase-8 inhibitor N-benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone inhibited apoptosis, but specific caspase-1 and caspase-3 inhibitors did not. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 30-85 caspase 3 Homo sapiens 236-245 10919674-5 2000 This apoptotic activity of E1A is accompanied by processing of caspase-3 and cleavage of poly(ADP-ribose) polymerase and can be significantly blocked by z-VAD-fmk Z-Val-Ala-Asp(OCH3)-CH2F and the caspase-3-specific inhibitor Z-DEVD-FMK Z-Asp(OCH3)-Glu-Val-Asp(OCH3)-CH2F. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 153-162 caspase 3 Homo sapiens 196-205 10864208-7 2000 Pre-exposure of the cells to the caspase-3-specific inhibitor DEVD-CHO partially reduced the mAb 225-induced PARP cleavage and apoptosis, whereas pre-exposure of the cells to the caspase pan-inhibitor z-VAD-fmk completely inhibited mAb 225-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 201-210 caspase 3 Homo sapiens 33-42 11201051-5 2000 A caspase-3 inhibitor z-VAD-FMK completely blocked the apoptosis, but a caspase-1 inhibitor (Ac-YVAD-CMK) and caspase-2 inhibitor (z-VDVAD-FMK) did not block the apoptosis, suggesting that caspase-3 might have a critical role in the execution process of apoptosis induced by RGD. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 22-31 caspase 3 Homo sapiens 2-11 10937621-9 2000 Significantly, cotreatment with Z-VAD-FMK or Ac-DMQD-CHO maintained COL2A1-reporter gene activity, indicating that the prevention of apoptosis by caspase-3 inhibition was sufficient to maintain cell functionality as assessed by the retention of type-II collagen promoter activity. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 32-41 caspase 3 Homo sapiens 146-155 10644366-4 2000 Specifically, in HEp-2 cells infected with d120, (i) a broad-range inhibitor of caspase activity, z-vad-FMK, efficiently blocked DNA fragmentation, (ii) cytochrome c was released into the cytoplasm, (iii) caspase-3 was activated inasmuch as poly(ADP-ribose) polymerase was cleaved, and (iv) chromatin condensation and fragmentation of cellular DNA were observed. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 98-107 caspase 3 Homo sapiens 205-214 10728920-7 2000 Pretreatment with caspase-3 inhibitors, Ac-DEVD-CHO and Z-VAD-FMK, inhibited lovastatin induced caspase-3 activity and DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 56-65 caspase 3 Homo sapiens 18-27 10728920-7 2000 Pretreatment with caspase-3 inhibitors, Ac-DEVD-CHO and Z-VAD-FMK, inhibited lovastatin induced caspase-3 activity and DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 56-65 caspase 3 Homo sapiens 96-105 10327056-6 1999 The caspase inhibitors (Z-DEVD-FMK and Z-VAD-FMK) suppressed CD437-induced CPP32-like caspase activation and apoptosis in both cell lines. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 39-48 caspase 3 Homo sapiens 75-80 10456673-7 1999 GC induced delta psi(m) disruption can be inhibited by the ICE-like inhibitor zVAD-fmk but not by ICE inhibitor tetrapeptide acetyl-Tyr-Val-Ala-Asp.chloromethylketone (YVAD-cmk) nor by caspase-3 inhibitor zDEVD. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 78-86 caspase 3 Homo sapiens 185-194 10229803-7 1999 z-Val-Ala-Asp-fluoromethyl ketone was a more powerful antagonist of caspase-3 processing, but prevented the shedding of CD4+ vesicles only partially and had no effect on that of PrPc+ ones. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-33 caspase 3 Homo sapiens 68-77 10697511-5 1999 In contrast, other inhibitors of caspases such as Z-DEVD-FMK and Z-VAD-FMK, inhibited the processing of the caspase 3 precursor p32 to 20-kDa and 17-kDa peptides, a result which suggests that these inhibitors inhibited other upstream caspases. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 65-74 caspase 3 Homo sapiens 108-117 10532355-5 1999 The activity of caspase-3 was remarkably increased when the cell was treated with EDCB, and this activity was nullified by Z-VAD-FMK, a well known caspase-3 inhibitor. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 123-132 caspase 3 Homo sapiens 16-25 10532355-5 1999 The activity of caspase-3 was remarkably increased when the cell was treated with EDCB, and this activity was nullified by Z-VAD-FMK, a well known caspase-3 inhibitor. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 123-132 caspase 3 Homo sapiens 147-156 10376529-2 1999 Our results show that TGFbeta-mediated nuclear fragmentation, observed in the Epstein-Barr virus-negative Burkitt"s Lymphoma cell line BL41, was abolished in the presence of the tripeptide caspase inhibitor zVAD-fmk or the specific caspase-3 inhibitor DEVD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 207-215 caspase 3 Homo sapiens 232-241 10224094-7 1999 Accordingly, although inhibition of caspase activity with zVAD-fmk blocked activation of caspase-3, FAK cleavage, and apoptosis, it neither affected dephosphorylation nor translocation of FAK or paxillin. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 58-66 caspase 3 Homo sapiens 89-98 10381635-11 1999 The inhibitor, zVAD-fmk suppressed Mn2+-triggered CPP32 activation and PARP cleavage and apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 15-23 caspase 3 Homo sapiens 50-55 9694885-8 1998 During Fas-mediated death, however, activation of caspase 3 is completely inhibited to zVAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 87-95 caspase 3 Homo sapiens 50-59 9973511-6 1999 Blocking experiments using caspase inhibitors with different specificities (DEVD-CHO, z-VAD-fmk, and YVAD-cmk), an enzymatic activity assay, and immunoblotting show that CPP32/caspase-3 play a prominent role in CD95-induced astrocyte death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 86-95 caspase 3 Homo sapiens 176-185 10048577-5 1999 z-VAD-FMK, t-butoxycarbonyl-aspartate-FMK (Boc-D-FMK), and z-IETD-FMK blocked the initial cleavage of procaspase 3, while z-DEVD-FMK, z-VEID-FMK, and z-VDVAD-FMK did not block the initial cleavage but had some effect on blocking apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-9 caspase 3 Homo sapiens 102-114 10487422-5 1999 Pretreatment with a potent caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (zVAD-fmk) inhibited antidepressant-induced CPP32/CPP32-like activity and apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 96-104 caspase 3 Homo sapiens 139-144 10487422-5 1999 Pretreatment with a potent caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (zVAD-fmk) inhibited antidepressant-induced CPP32/CPP32-like activity and apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 96-104 caspase 3 Homo sapiens 145-150 9581784-7 1998 Z-VAD-FMK also inhibited cleavage of substrates such as cysteine protease CPP32 and nuclear lamins, whereas cleavage of poly(ADP-ribose) polymerase was partially inhibited during infection with an E1B 19K mutant. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-9 caspase 3 Homo sapiens 74-79 9973511-6 1999 Blocking experiments using caspase inhibitors with different specificities (DEVD-CHO, z-VAD-fmk, and YVAD-cmk), an enzymatic activity assay, and immunoblotting show that CPP32/caspase-3 play a prominent role in CD95-induced astrocyte death. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 86-95 caspase 3 Homo sapiens 170-175 9973225-13 1999 This was evidenced by the fact that chemotherapy agents that synergized with TRAIL (e.g., doxorubicin) themselves caused cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP), and their toxicity was blocked by the caspase inhibitor Z-Val-Ala-Asp(OMe)-CH2 (ZVAD-fmk). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 263-271 caspase 3 Homo sapiens 133-142 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 30-83 caspase 3 Homo sapiens 334-343 9894610-4 1998 Here we report that Bcl-2 and benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD-fmk), a broad spectrum caspase inhibitor, prevent loss of mitochondrial membrane potential (delta psi m) and the production of reactive oxygen species (ROS) caused by GC, while acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), an inhibitor of the caspase-3 family proteases, does not. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 85-93 caspase 3 Homo sapiens 334-343 9685336-8 1998 Pretreatment with carbobenzoxy-Asp-CH2OC(O)-2,6-dichlorobenzene or Z-Val-Ala-Asp-fluoromethylketone was able to block the caspase-3-mediated production of the 38-kDa fragment both in situ and in vitro. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 67-99 caspase 3 Homo sapiens 122-131 9694885-10 1998 Our results demonstrate that whereas Fas-mediated activation of caspase 3 requires an upstream caspase activity that is zVAD-fmk-sensitive, the initial cleavage of caspase 3 during granule-mediated cell death is insensitive to zVAD-fmk, suggesting that caspase 3 is cleaved directly by granzyme B in vivo. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 120-128 caspase 3 Homo sapiens 64-73 9264376-4 1997 We found that CPP32 is activated during camptothecin-induced apoptosis, and that N-benzyloxycarbony-Val-Ala-Asp (O-methyl) -fluoromethyketone (Z-VAD-fmk), a cell permeable caspase inhibitor blocks all features of apoptosis: morphological changes, cleavage of caspase 3 (CPP32/Yama/Apopain) and poly(ADP-ribose) polymerase, lamin B degradation and DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 143-152 caspase 3 Homo sapiens 259-268 9425165-6 1998 However, the protease CPP32, a downstream molecule of the CD95 pathway, was activated in UV-exposed HaCaT cells, and UV-induced apoptosis was blocked by the ICE protease inhibitor zVAD, implying that at least similar downstream events are involved in CD95- and UV-induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 180-184 caspase 3 Homo sapiens 22-27 9541007-5 1998 The wide-spectrum caspase inhibitor Z-VAD-FMK and Z-DEVD-FMK, an inhibitor of the downstream caspases 3 (CPP32, Yama) and 7, both inhibited apoptosis induced by all the lipids tested. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 36-45 caspase 3 Homo sapiens 105-110 9541007-5 1998 The wide-spectrum caspase inhibitor Z-VAD-FMK and Z-DEVD-FMK, an inhibitor of the downstream caspases 3 (CPP32, Yama) and 7, both inhibited apoptosis induced by all the lipids tested. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 36-45 caspase 3 Homo sapiens 112-116 9264376-4 1997 We found that CPP32 is activated during camptothecin-induced apoptosis, and that N-benzyloxycarbony-Val-Ala-Asp (O-methyl) -fluoromethyketone (Z-VAD-fmk), a cell permeable caspase inhibitor blocks all features of apoptosis: morphological changes, cleavage of caspase 3 (CPP32/Yama/Apopain) and poly(ADP-ribose) polymerase, lamin B degradation and DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 143-152 caspase 3 Homo sapiens 270-275 9264376-4 1997 We found that CPP32 is activated during camptothecin-induced apoptosis, and that N-benzyloxycarbony-Val-Ala-Asp (O-methyl) -fluoromethyketone (Z-VAD-fmk), a cell permeable caspase inhibitor blocks all features of apoptosis: morphological changes, cleavage of caspase 3 (CPP32/Yama/Apopain) and poly(ADP-ribose) polymerase, lamin B degradation and DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 143-152 caspase 3 Homo sapiens 276-280 9264376-4 1997 We found that CPP32 is activated during camptothecin-induced apoptosis, and that N-benzyloxycarbony-Val-Ala-Asp (O-methyl) -fluoromethyketone (Z-VAD-fmk), a cell permeable caspase inhibitor blocks all features of apoptosis: morphological changes, cleavage of caspase 3 (CPP32/Yama/Apopain) and poly(ADP-ribose) polymerase, lamin B degradation and DNA fragmentation. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 143-152 caspase 3 Homo sapiens 281-288 8670109-2 1996 We now demonstrate that benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK), an ICE-like protease inhibitor, inhibits apoptosis by preventing the processing of CPP32 to its active form. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 80-89 caspase 3 Homo sapiens 175-180 8647264-7 1996 A tripeptide inhibitor of ICE family cysteine proteases, Z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) inhibits ionomycin- and AgR-triggered CPP32 activation, PARP cleavage and apoptosis, but not growth arrest, in Ramos-BL B cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 57-89 caspase 3 Homo sapiens 139-144 8647264-7 1996 A tripeptide inhibitor of ICE family cysteine proteases, Z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) inhibits ionomycin- and AgR-triggered CPP32 activation, PARP cleavage and apoptosis, but not growth arrest, in Ramos-BL B cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 91-99 caspase 3 Homo sapiens 139-144 30953339-12 2019 The Z-VAD-fmk significantly inhibited cell death through the suppression of caspase-3 expression in MG-63 cells treated with reversine. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 4-13 caspase 3 Homo sapiens 76-85 32764479-7 2020 We observed enhanced effector caspase-3 activation and could successfully rescue the cells using the pan-caspase inhibitor zVAD-fmk, but not necrostatin-1. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 123-131 caspase 3 Homo sapiens 30-39 32658903-6 2020 An Apoptosis inhibitor (z-VAD-FMK) suppressed the enhancement of cell death as well as the levels of cleaved caspase-3 protein in PKClambda deficient ALDH1high cells. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 24-33 caspase 3 Homo sapiens 109-118 32145587-7 2020 Interestingly, DSF/Cu induced caspase-3 activation was partly blocked by Z-VAD-FMK (zVAD), a pan-caspase inhibitor, indicating at caspase-dependent and -independent paths involved in DSF/Cu induced myeloma cell apoptosis machinery. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 73-82 caspase 3 Homo sapiens 30-39 32145587-7 2020 Interestingly, DSF/Cu induced caspase-3 activation was partly blocked by Z-VAD-FMK (zVAD), a pan-caspase inhibitor, indicating at caspase-dependent and -independent paths involved in DSF/Cu induced myeloma cell apoptosis machinery. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 84-88 caspase 3 Homo sapiens 30-39 32539919-5 2020 Z-VAD-FMK, a caspase inhibitor, significantly antagonized UA- and Oxa-activated caspase-3, caspase-8, and caspase-9 and induced apoptosis. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 0-9 caspase 3 Homo sapiens 80-89 11285189-6 2001 A general caspase inhibitor, z-VAD-fmk, dramatically decreased cytotoxicity in MSC-treated HL-60 cells and several other apoptotic features, such as, caspase-3 activation, the apoptotic DNA ladder, TUNEL-positive staining and the DNA double-strand break. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 29-38 caspase 3 Homo sapiens 150-159 34673182-5 2021 NO scavenging agent (haemoglobin) and free radical scavenging agent (N-acetylcysteine) partially reversed mitochondrial damage, and Z-VAD-FMK increased the levels of GH and decreased the levels of caspase 3, 8 and 9, while haemoglobin decreased the levels of caspase 3, 8 and 9, indicating that NO is the primary target of DON-mediated inhibition. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 132-141 caspase 3 Homo sapiens 197-215 34822470-3 2021 Act V-induced apoptosis was characterized by mitochondrial dysfunction, with loss of mitochondria membrane potential (MMP) and cytochrome c release, which then activated cleaved caspase-9, cleaved caspase-3, and cleaved PARP, revealing that it was related to the mitochondrial pathway, and the apoptotic trendency can be reversed by caspase inhibitor Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 351-360 caspase 3 Homo sapiens 197-206 34084200-12 2021 Moreover, the apoptosis-inducing effect of Benjakul, 6-shogaol, and plumbagin at the highest dose, via the caspase cascade was confirmed by time-dependent induction of caspase-3 activity, followed by its complete reduction and abolished sub-G1 peaks upon addition of Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 267-276 caspase 3 Homo sapiens 168-177 33217539-9 2021 Furthermore, ED-71-induced apoptosis was weakened after adding 3-methyladenine and ED-71-induced early autophagy was weakened by caspase-3 inhibitor (Z-VAD-FMK), which indicated the two processes active each other in the presence of ED-71. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 150-159 caspase 3 Homo sapiens 129-138 32624316-7 2021 When CAR cells were treated with AITC, activation of caspase-3 and caspase-9 by AITC was observed and could be reversed by Z-VAD-fmk (pan-caspase inhibitor). benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 123-132 caspase 3 Homo sapiens 53-62 32581406-9 2020 Among the compounds, VTC exhibited the highest cytotoxicity, which was partially inhibited by a caspase 3 inhibitor, Z-VAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 117-126 caspase 3 Homo sapiens 96-105 30777466-9 2019 Bufalin decreased cell viability, increased cell death as well as caspase-3 downstream target (cleaved PARP) accumulation, and these actions were significantly blocked by pan-caspase inhibitor zVAD-FMK. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 193-201 caspase 3 Homo sapiens 66-75 30934696-7 2019 Caspase-3 activation was also evidenced using a caspase-3 inhibitor, z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 69-78 caspase 3 Homo sapiens 0-9 30934696-7 2019 Caspase-3 activation was also evidenced using a caspase-3 inhibitor, z-VAD-fmk. benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone 69-78 caspase 3 Homo sapiens 48-57